摘要
目的:探讨EGFR-TKI靶向联合放疗、化疗对Ⅳ期EGFR突变型非小细胞肺癌(NSCLC)的临床效果。方法:对我院2017年1月~2020年6月收治的105例Ⅳ期EGFR突变型NSCLC患者进行回顾性分析,其中36例接受EGFR-TKI靶向单药治疗(单一治疗组)、37例接受EGFR-TKI靶向联合三维适型放疗(联合放疗组)、32例接受EGFR-TKI靶向联合含铂类的双药化疗(联合化疗组),对比三组的近期总有效率、不良反应、1年生存率及无进展生存期(PFS)。结果:联合放疗组ORR为41%、联合化疗组为63%,优于单一治疗组的17%。联合化疗组恶心、呕吐反应发生率高于单一治疗组,但三组间其他不良反应如皮疹、腹泻、肝功能损伤、骨髓抑制等无统计学意义。联合放疗组1年生存率为92%、联合化疗组为97%,较单一治疗组的72%高。联合放疗组的中位PFS为8个月,联合化疗组为10个月,高于单一治疗组的6个月。结论:Ⅳ期EGFR突变型NSCLC患者行EGFR-TKI靶向联合放疗、化疗治较单一EGFR-TKI靶向治疗疗效好,预后更能获益。
Objective To investigate the efficacy of EGFR-TKI-targeted combined with radiotherapy or chemotherapy on Ⅳ non-small cell lung cancer(NSCLC)patients with EGFR mutations.Methods A total of 105 patients with EGFR mutations and Ⅳ NSCLC from January 2017 to June 2019 were retrospectively analyzed,among whom,36 patients were treated with EGFR-TKI-targeted monotherapy(single treatment group),37 patients were treated with EGFR-TKI-targeted combined with three-dimensional conformal radiotherapy(combined radiotherapy group),and 32 patients were treated with EGFR-TKI-targeted combined with dual-drug chemotherapy with platinum(combination chemotherapy group).Comparing the short-terms efficacy,adverse events,1-year survival and progression-free survival of the three groups.Results The ORR was 41%in combined radiotherapy group and 63% in combination chemotherapy group,higher than that(17%)of single treatment group.The rate of nausea and vomiting were more frequent in combination chemotherapy group than single treatment group,while other adverse events such as rash,diarrhea,liver function injury,and myelosuppression had no significant differences in the three groups.1-year survival rate was 92% in combined radiotherapy group and 97% in combination chemotherapy group,higher than that(72%)of single treatment group.The median PFS was 8 months in combined radiotherapy group and 10 months in combination chemotherapy group,higher than that(6 months)of single treatment group.Conclusion The patients with EGFR mutations and IV NSCLC could benefit from EGFR-TKI-targeted combined with radiotherapy or chemotherapy with a relativeiy high ORR,1-year survival rate and longer PFS.
作者
郝娟
周光华
陈忆玲
Hao Juan;Zhou Guang-hua;Chen yi-ling(Department of Oncology,The Second Affiliated Hospital of Hunan Normal University,No 921 Hospital of PLA Joint Logistics Support Force,Changsha 410003,China)
出处
《湖南师范大学学报（医学版）》
2021年第2期109-112,共4页
Journal of Hunan Normal University(Medical Sciences)
